# A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

> **NCT07281001** · NA · RECRUITING · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 60 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Trastuzumab Deruxtecan

## Interventions

- **DRUG:** T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.

## Key facts

- **NCT ID:** NCT07281001
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281001, "A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07281001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*